{"id":110,"date":"2023-07-08T06:40:57","date_gmt":"2023-07-08T06:40:57","guid":{"rendered":"https:\/\/indiangenericmedicines.com\/?post_type=product&#038;p=110"},"modified":"2025-08-04T09:48:26","modified_gmt":"2025-08-04T09:48:26","slug":"buy-lynparza-tablets","status":"publish","type":"product","link":"https:\/\/indiangenericmedicines.com\/af\/oncology\/buy-lynparza-tablets\/","title":{"rendered":"LYNPARZA"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Lynparza (<\/span><span style=\"font-weight: 400;\">Olaparib 100 mg\/150 mg) <\/span><span style=\"font-weight: 400;\">is a poly (ADP-ribose) polymerase (PARP) inhibitor widely used:<\/span><\/p>\n<p style=\"text-align: justify;\"><b>Ovarian cancer:<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">For the maintenance therapy of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Along with the medicine bevacizumab for the maintenance therapy of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is linked with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and\/or genomic instability.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">For the maintenance therapy of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are either in complete or partial response to platinum-based chemotherapy.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><b>Breast cancer:<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">For the adjuvant therapy of adults with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">For the therapy of adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><b>Pancreatic cancer:<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">For the maintenance therapy of adults with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><b>Prostate cancer:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400; text-align: justify;\"><span style=\"font-weight: 400;\">For the therapy of adults with deleterious or suspected deleterious germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior therapy with enzalutamide or abiraterone.<\/span><\/li>\n<li style=\"font-weight: 400; text-align: justify;\"><span style=\"font-weight: 400;\">Along with abiraterone and prednisone or prednisolone for the treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). <\/span><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<ul>\n<li><b>Medicine Name-<\/b><span style=\"font-weight: 400;\"> Lynparza<\/span><\/li>\n<li><b>API-<\/b><span style=\"font-weight: 400;\"> Olaparib<\/span><\/li>\n<li><b>Packaging-<\/b><span style=\"font-weight: 400;\"> Tablets<\/span><\/li>\n<li><b>Strength- <\/b><span style=\"font-weight: 400;\">100 mg\/150 mg<\/span><\/li>\n<li><b>Manufactured by- <\/b><span style=\"font-weight: 400;\">AstraZeneca<\/span><\/li>\n<\/ul>","protected":false},"featured_media":4161,"template":"","meta":[],"product_brand":[],"product_cat":[18],"product_tag":[1093,1092],"class_list":["post-110","product","type-product","status-publish","has-post-thumbnail","product_cat-oncology","product_tag-olaparib-price-in-india","product_tag-olaparib-supplier","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/product\/110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/media\/4161"}],"wp:attachment":[{"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/media?parent=110"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/product_brand?post=110"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/product_cat?post=110"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/indiangenericmedicines.com\/af\/wp-json\/wp\/v2\/product_tag?post=110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}